Publication

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors not recorded

Ann Oncol2016PMID 26884591PMC4843186stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (16)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 16

cancerMalignant Neoplasmcivic_curation1.00
drugALK/TRK Inhibitor TSR-011civic_curation1.00
drugCrizotinibcivic_curation1.00
drugEntrectinibcivic_curation1.00
drugLarotrectinibcivic_curation1.00
geneNTRK1civic_curation1.00
geneNTRK2civic_curation1.00
geneNTRK3civic_curation1.00
variantNTRK1 Fusioncivic_curation1.00
variantNTRK1 Fusioncivic_curation1.00
variantNTRK1 Fusioncivic_curation1.00
variantNTRK2 Fusioncivic_curation1.00
variantNTRK2 Fusioncivic_curation1.00
variantNTRK2 Fusioncivic_curation1.00
variantNTRK3 Fusioncivic_curation1.00
variantNTRK3 G623Rcivic_curation1.00

Curated evidence

Evidence citing this paper (11)

civicCuratedShowing 1–11 of 11 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10098 fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NT… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK1 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10096 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10099 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib in cell viability assays: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK3 Fusion3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID11087 BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
Crizotinib	Mammary Analogue Secretory CarcinomaUNRESOLVED	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID1870 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 1… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
Entrectinib	Mammary Analogue Secretory CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	accepted	EID1869 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK3 Fusion + NTRK3 G623R2
ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID10093 BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
Entrectinib	Mammary Analogue Secretory CarcinomaUNRESOLVED	Predictive	C	Supports Resistance	4	accepted	EID1874 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK1 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10095 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK1 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID10094 BaF3 cells transduced with a number of NTRK fusions demonstrated sensitivity to entrectinib. IC50 values were measured from cell viability assays (Cell Titer Glo) following 72-hour incubation with ent… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10097 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic